• Pil Sang Song, Young Bin Song, Joo-Yong Hahn, Doo-Il Kim, Jeong Hoon Yang, Seung-Hyuk Choi, Jin-Ho Choi, Hyeon-Cheol Gwon, and Korean Endeavor Registry Investigators.
• Division of Cardiology (PSS, D-IK), Department of Internal Medicine, Inje University Haeundae Paik Hospital, Busan, Korea; and Division of Cardiology (YBS, J-YH, JHY, S-HC, J-HC, H-CG), Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
• Am. J. Med. Sci. 2013 Dec 1; 346 (6): 479485479-85.

BackgroundThe impact of gender on outcomes after percutaneous coronary intervention (PCI) with second-generation drug-eluting stents is not known in Asian patients. The authors studied outcomes after PCI with zotarolimus-eluting stent in unselected consecutive series of Asian patients according to gender.MethodsOutcomes among patients treated with zotarolimus-eluting stents from multicenter registry were evaluated by gender. The primary outcome was major adverse cardiac events, composite of cardiac death, myocardial infarction and target lesion revascularization at 1 year.ResultsOf 2,840 patients, 855 (30.1%) were women. Comparatively, women were older; more frequently had diabetes, hypertension, and dyslipidemia; less frequently women were current smokers, had previous myocardial infarctions and previous PCIs; were more likely to have culprit lesions in left anterior descending coronary artery; and underwent more multilesion PCIs. After adjustment for baseline differences, women were still at lower risk of major adverse cardiac events (38 [4.4%] versus 137 [6.9%], adjusted hazard ratio [HR]: 0.52, 95% confidence interval [CI]: 0.30-0.89, P = 0.018), mainly driven by target lesion revascularization (24 [2.8%] versus 106 [5.3%], adjusted HR: 0.41, 95% CI: 0.24-0.70, P = 0.001) at 1 year, although rates of cardiac death, myocardial infarction and stent thrombosis were similar between genders. These results were consistent after propensity score-matched population analysis (for major adverse cardiac events, adjusted HR: 0.36, 95% CI: 0.18-0.69, P = 0.012; for target lesion revascularization, adjusted HR: 0.32, 95% CI: 0.15-0.69, P = 0.004) and were also constant among various high-risk subgroups.ConclusionsDespite greater baseline clinical and angiographic risk, the use of the zotarolimus-eluting stent is associated with favorable outcomes among Asian women treated with PCI.

29 keywords...

hide…